STOK | Stoke Therapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	14.21 - 15.31
52 Week Range	3.35 - 17.58
Beta	0.87
Implied Volatility	72.22%
IV Rank	20.53%
Day's Volume	305,596
Average Volume	610,162
Shares Outstanding	52,647,800
Market Cap	773,922,660
Sector	Healthcare
Industry	Biotechnology
IPO Date	2019-06-19

Valuation
Profitability
Growth
Health
P/E Ratio	-6.77
Forward P/E Ratio	-3.41
EPS	-2.17
1YR Price Target	27.50
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	110
Country	USA
Website	STOK

Stoke Therapeutics Inc is engaged in addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, it is developing antisense oligonucleotides (ASOs) to selectively restore protein levels.

STOK's peers: ACET, ACIU, ADAP, ADCT, ADMA, ADVM, AGIO, AKRO, ALEC, ALVR, ALXO, ARCT, ARVN, ASND, BCYC, BDTX, CABA, CERE, CYTK, DNLI, DSGN, DTIL, DYN, ENTA, ERAS, ETNB, FDMT, FGEN, FHTX, FULC, GALT, GBIO, GHRS, GLUE, GOSS, HOWL, IFRX, IGMS, IKNA, IMVT, INBX, INKT, IOBT, IPSC, KOD, KZR, LBPH, LEGN, MDGL, MDXG, MORF, MTNB, NRIX, OMER, PASG, PHVS, PLRX, PRAX, PRTA, PSTX, PTGX, RAPT, RCKT, RGNX, RLAY, RNA, RVMD, RVNC, RYTM, SAGE, SLDB, SRRK, FIXX, HARP, BCEL, TCRR, STTK, SVRA, SWTX, SYBX, SYRS, TARS, TCRT, TNGX, TNYA, TSHA, TSVT, TVTX, TYRA, VALN, VCEL, VIRX, VNDA, XBIT, XOMA, ZYME, PROK, ZVRA

*Chart delayed

Analyzing fundamentals for STOK we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is passable. For more detailed analysis please see STOK Fundamentals page.

Watching at STOK technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on STOK Technicals page.